First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Related Keywords

Elias Jabbour , ,First Report ,Comparing Ponatinib ,Newly Diagnosed ,Acute Lymphocytic Leukemia ,Call Cancer ,All Leukemia ,Ponatinib ,Imatinib ,Phallcon ,Ph Positive ,Oph All ,Tyrosine Kinase Inhibitors ,Tki Therapy ,Combination Therapy ,Bcr Abl ,T3315i ,Ponatinib Dose ,Ponatinib Dosing ,Complete Response ,Survival Data ,Adverse Events ,Drug Adverse Event ,Mrd Negativity ,Mrd Negative ,Duration Of Response ,Crossover Therapy ,Sequencing Therapy ,Event Free Survival ,Efs Data ,Progression Free Survival ,Pfs Data ,Overall Survival ,Dose Discontinuation ,Dose Reduction ,